NCT02975700 - A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

August 31, 2018

Study Completion Date

October 14, 2024

Conditions

Melanoma

Interventions

DRUG

PLX3397

1000 mg/day (400 mg in the morning and 600 mg in the evening)

Trial Locations (5)

Beijing Cancer Hospital, Beijing

Sun Yat-sen Hospital, Guangzhou

Seoul National University Hospital, Seoul

Samsung Medical Center, Seoul

Severance Hospital, Yonsei University Health System, Seoul